Elekta AB stock (SE0000163628): earnings outlook and innovation pipeline in focus

Radiation therapy specialist Elekta AB remains in the spotlight as investors digest the latest earnings, margin trends and order intake. How stable is the growth story in cancer treatment technology for US and global markets?

Elekta AB, a Sweden-based specialist for radiation therapy and radiosurgery solutions, remains under close watch by global investors as the market processes its latest earnings and guidance signals. The company’s positioning in cancer care technology, especially in linear accelerators and software, keeps the stock relevant for both European and US-focused healthcare portfolios.

As of: 27.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Elekta
• Sector/industry: Medical technology, radiation oncology
• Headquarters/country: Sweden
• Core markets: Hospitals and cancer centers in Europe, North America and emerging markets
• Key revenue drivers: Radiation therapy systems, radiosurgery platforms, oncology software and service contracts
• Home exchange/listing venue: Nasdaq Stockholm (ticker: EKTAb)
• Trading currency: Swedish krona (SEK)

Elekta AB: core business model

Elekta AB focuses on technologies that enable the precision treatment of cancer and certain brain disorders with radiation. The group’s portfolio typically includes linear accelerators, stereotactic radiosurgery systems and treatment planning software that help clinicians deliver high doses of radiation to tumors while sparing healthy tissue. This combination of hardware and software is central to Elekta’s business model and recurring revenue potential.

The company’s solutions are used by hospitals, academic medical centers and specialized oncology clinics worldwide. In practice, Elekta earns revenue from the sale of large capital equipment, such as radiation therapy machines, followed by long-term service contracts, upgrades and software licenses. This mix can create a relatively visible revenue stream over time, as installed systems require regular maintenance and compliance updates.

Given the global burden of cancer and demographic trends in many markets, demand for advanced radiation therapy remains structurally supported. Health systems are looking for ways to increase precision, reduce side effects and improve patient throughput, areas where Elekta’s product roadmap and software integration are strategically important. For investors, the company sits at the intersection of medical technology, digitalization of healthcare and demographic change.

Main revenue and product drivers for Elekta AB

Elekta’s revenue base is built around several key product families. Linear accelerators, often referred to as linacs, are at the heart of conventional external beam radiation therapy. These systems generate high-energy beams that can be shaped and modulated to match tumor volumes. Linac sales are capital intensive and depend on hospital investment cycles, tender processes and reimbursement conditions in each country.

A second important driver is stereotactic radiosurgery and stereotactic body radiation therapy solutions. These enable extremely precise delivery of high-dose radiation, often in fewer treatment sessions. Such precision platforms are particularly relevant for tumors in the brain and spine, and for certain metastatic lesions. The technology requires close integration of imaging, planning software and delivery hardware, which can deepen customer relationships once a system is installed.

Software and services form another pillar of Elekta’s model. Oncology information systems and treatment planning software help clinicians manage patient data, design dose distributions and coordinate treatment workflows. Software licenses, upgrades and cloud-based offerings can generate recurring income with higher margins compared to hardware. In addition, service contracts for installed equipment provide revenue visibility and can soften the cyclical impact of capital budget fluctuations.

Geographically, Elekta’s business is diversified across Europe, the Americas and Asia-Pacific. The US remains one of the most important single-country markets for advanced radiation therapy, given its large population, high cancer incidence and established reimbursement mechanisms. At the same time, emerging markets in Asia, Latin America and parts of Eastern Europe represent growth opportunities as health systems invest in modern oncology infrastructure. Currency movements, public tender timing and regulatory approvals can, however, influence quarterly order intake.

Industry trends and competitive position

The radiation oncology market is shaped by several trends that influence Elekta’s strategic decisions. One major driver is the move toward more precise, image-guided and adaptive radiation therapy. This involves integrating imaging modalities, such as MRI or cone-beam CT, with treatment delivery to adjust plans based on tumor and organ motion. Companies in this field invest heavily in R&D to offer platforms that can adapt in real time, a development that can change competitive dynamics over the next decade.

Another trend is the digitalization of oncology workflows. Hospitals are seeking integrated software solutions that connect planning, treatment and follow-up, while also interfacing with broader hospital information systems. Vendors that provide interoperable platforms, robust cybersecurity and cloud capabilities can gain an advantage. In this environment, Elekta’s ability to expand its software footprint and offer end-to-end solutions is a key differentiator and a potential margin lever.

The competitive landscape includes large multinational medtech players and specialized oncology technology firms. Competition often centers on clinical capabilities, reliability, service quality and total cost of ownership over the life cycle of equipment. For many customers, long-term relationships, local service presence and training support are as important as the initial purchase price. Elekta’s installed base and history in radiation therapy give it a foundation, but it must continuously innovate to defend and grow its share in a market characterized by rapid technological progress.

Conclusion

Elekta AB occupies a central niche in radiation oncology, combining capital equipment with software and long-term service. The company’s exposure to the global cancer treatment market, its installed base and its focus on precision therapies underpin its strategic relevance for healthcare investors. At the same time, competition, reimbursement conditions, tender timing and currency effects create ongoing uncertainties that can influence earnings visibility and share price volatility. For US-focused investors, Elekta offers indirect exposure to structural trends in oncology technology beyond domestic medtech names, but it also introduces international regulatory and currency dimensions that warrant careful monitoring.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.